The DOI matches its Crossref record; 1 of the 1 references it cites were found in a registry or an index.
Vascular endothelial growth factor‐targeted therapy for the treatment of adult metastatic Xp11.2 translocation renal cell carcinoma
Open accessAbstract
BACKGROUND: Adult “translocation” renal cell carcinoma (RCC), bearing transcription factor E3 (TFE3) gene fusions at Xp11.2, is a recently recognized, unique entity for which prognosis and therapy remain poorly understood. In the current study, the authors investigated the effect of vascular endothelial growth factor (VEGF)‐targeted therapy in this distinct subtype of RCC. METHODS: A retrospective review was conducted to describe the clinical characteristics and outcome of adult patients with metastatic Xp11.2 RCC who had strong TFE3 nuclear immunostaining and received anti‐VEGF therapy. Tumor response to anti‐VEGF therapy was evaluated using Response Evaluation Criteria in Solid Tumors (RECIST) criteria. The Kaplan‐Meier method was used to estimate progression‐free survival (PFS) and overall survival (OS) distributions. RESULTS: Fifteen patients were identified, of whom 10, 3, and 2 received sunitinib, sorafenib, and monoclonal anti‐VEGF antibodies, respectively. The median follow‐up was 19.1 months, the median age of the patients was 41 years, and the female:male ratio was 4:1. Initial histologic description included clear cell (n = 8 patients), papillary (n = 1 patient), or mixed clear cell/papillary RCC (n = 6 patients). Five patients had received prior systemic therapy. Five patients had undergone fluorescent in situ hybridization analysis and all demonstrated a translocation involving chromosome Xp11.2. When treated with VEGF‐targeted therapy, 3 patients achieved a partial response, 7 patients had stable disease, and 5 patients developed progressive disease. The median PFS and OS of the entire cohort were 7.1 months and 14.3 months, respectively. CONCLUSIONS: Adult‐onset, translocation‐associated metastatic RCC is an aggressive disease that affects a younger population of patients with a female predominance. In the current study, VEGF‐targeted agents appeared to demonstrate some efficacy. Cancer 2010. © 2010 American Cancer Society.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Jemal, A., Siegel, R., Ward, E., Hao, Y., Xu, J., & Thun, M. J. (2009) · CA: A Cancer Journal for Clinicians · doi:10.3322/caac.20006 · Cited by 9,709
Cited by
Shuch, B., Amin, A., Armstrong, A. J., Eble, J. N., Ficarra, V., Lopez-Beltran, A., Martignoni, G., Rini, B. I., & Kutikov, A. (2015) · European Urology · doi:10.1016/j.eururo.2014.04.029 · Cited by 531
Molecular genetics and cellular features of TFE3 and TFEB fusion kidney cancers
Kauffman, E. C., Ricketts, C. J., Rais-Bahrami, S., Yang, Y., Merino, M. J., Bottaro, D. P., Srinivasan, R., & Linehan, W. M. (2014) · Nature Reviews Urology · doi:10.1038/nrurol.2014.162 · Cited by 313
Metadata
- Authors
- Choueiri, T. K., Lim, Z. D., Hirsch, M. S., Tamboli, P., Jonasch, E., McDermott, D. F., Cin, P. D., Corn, P., Vaishampayan, U., Heng, D. Y. C., & Tannir, N. M.
- Venue
- Cancer
- Publisher
- Wiley
- Published
- 2010-11-03
- Volume
- 116
- Issue
- 22
- Pages
- 5219-5225
- ISSN
- 0008-543X (ISSN-L)
- 1097-0142
- OpenAlex
- W2000438429
- Cited by
- 162
- References
- 1
- FWCI
- 6.64
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.